Ligand Pharmaceuticals reported $1.13B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 57.3B 19M Jun/2026
Anika Therapeutics USD 0 0 Mar/2025
Arrowhead Research USD 983.69M 5.77M Jun/2026
Baxter International USD 9.67B 20M Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Enviri Corporation USD 1.44B 3.08M Dec/2024
Gilead Sciences USD 26.25B 4.07B Jun/2026
GlaxoSmithKline GBP 18.24B 818M Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 544.86M 180.93M Sep/2026
Intrexon USD 0 13.82M Jun/2024
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Ligand Pharmaceuticals USD 1.13B 679.48M Jun/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Merck USD 53.91B 4.79B Jun/2026
Pacira USD 293.59M 69.53M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 40.11M 774K Jun/2026